Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06159699

Telecommunication Technology-based Online Survey

The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. The cohort is built using telecommunication approaches. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics will be assessed. The continuous depersonalized online survey is performed using the original informational resources in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Risk Factors COVID-19 Coronaviridae Infections Coronavirus Infections Drug Interactions Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral Polypharmacy RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Self Medication Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tomsk National Research Medical Center, Russian Academy of Sciences

Tomsk, 634012, Russia

Location status: Recruiting

Location contact

Nina D Anfinogenova, PhD

CONTACT

[email protected]

+73822554111

About this study

Polypharmacy-associated serious drug-drug interactions and adverse drug reactions may increase the risk of morbidity and mortality in the population, especially in cardiovascular patients. Insufficient patient compliance to treatment and potential self-medication overlap with behavioral, psychosocial, demographic, and environmental conditions and pose new challenges for the population striving to achieve active longevity. These issues have been especially relevant during and after the COVID-19 pandemic. The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. Telecommunication approaches are used for the formation of study cohort. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics of study cohort will be assessed. The continuous depersonalized online survey is performed using the original informational resource in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The acquired data may lay a foundation for the development decision support system for control of previously unrecognized or poorly recognized risk factors. The study will enroll as least 2000 respondents aged 18 years and older. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation. Both websites have built-in functionality for downloading survey results in tabular format (.xls, .csv). All the respondents are required to sign the informed consent form electronically according to local legislation and international standards of ethical research. Considering that no physical medical examinations or interventions are involved in the study, and all data undergo complete depersonalization, participation in this study does not pose any risks for respondents. Financial support for the study is provided by the Russian Science Foundation (project No. 22-15-00313). Respondents will not be covered by insurance due to the non-interventional nature of the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age of 18 years and older
  • signing the informed concent form online
  • completion of the entire questionnaire

Exclusion criteria

  • age under 18 years
  • refuse to sign the informed concent form

Treatment and study plan

Online survey

Other

The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.

Other names: Telecommunication-Based Survey

Genetic testing

Diagnostic Test

Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.

Other names: Genetic Polymorphisms of Drug-Metabolizing Enzymes

Primary outcomes

  1. Incidence of serious drug-drug interactions (percent)

    Time frame: Five years

    Incidence of serious drug-drug interactions (DDIs) is assessed as a percentage (%) of completed survey questionnaires associated with serious DDIs relative to the size of respondent population.

  2. Median number of serious drug-drug interactions (n)

    Time frame: Five years

    Median number of serious drug-drug interactions is assessed per one completed survey questionnaire containing information on pharmacotherapy.

Secondary outcomes

  1. Incidence of polypharmacy (percent)

    Time frame: Five years

    Polypharmacy refers to using five or more medications. Incidence of polypharmacy is assessed as a percentage (%) of completed survey questionnaires reporting polypharmacy relative to the size of respondent population.

  2. Incidence of MRI administration (percent)

    Time frame: Two years

    Incidence of magnetic resonance tomography (MRI) administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing MRI procedure for the past two years relative to the size of respondent population.

  3. Incidence of CT administration (percent)

    Time frame: Two years

    Incidence of computed tomography (CT) administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing CT procedure for the past two years relative to the size of respondent population.

  4. Incidence of diagnostic ultrasound administration (percent)

    Time frame: Two years

    Incidence of diagnostic ultrasound administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing ultrasonography procedure for the past two years relative to the size of respondent population.

  5. Incidence of diagnostic X-ray administration (percent)

    Time frame: Two years

    Incidence of diagnostic X-ray administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing X-ray for the past two years relative to the size of respondent population.

  6. Incidence of scintigraphy administration (percent)

    Time frame: Two years

    Incidence of scintigraphy administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing scintigraphy for the past two years relative to the size of respondent population.

  7. Incidence of chest fluoroscopy administration (percent)

    Time frame: Two years

    Incidence of chest fluoroscopy administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing chest fluoroscopy for the past two years relative to the size of respondent population.

  8. Clinically significant CYP2D6 gene polymorphisms

    Time frame: Two months

    Clinically significant CYP2D6 gene polymorphisms will be identified by diagnostic sequencing using EDTA whole blood.

  9. Clinically significant ACE gene polymorphisms

    Time frame: Two months

    Clinically significant ACE gene polymorphisms will be identified by real-time PCR with melting curve detection using EDTA whole blood.

  10. Clinically significant UGT1A1 gene polymorphisms

    Time frame: Two months

    Clinically significant UGT1A1 gene polymorphisms will be identified by real-time PCR with melting curve detection using EDTA whole blood.

  11. Clinically significant CYP2C9 gene polymorphisms

    Time frame: Two months

    Clinically significant CYP2C9 gene polymorphisms will be identified by real-time PCR with melting curve detection using EDTA whole blood.

  12. Clinically significant CYP2C19 gene polymorphisms

    Time frame: Two months

    Clinically significant CYP2C19 gene polymorphisms will be identified by real-time PCR with melting curve detection using EDTA whole blood.

Study contacts

Contact information is provided by the study sponsor or research team.

Nina D Anfinogenova, PhD

CONTACT

[email protected]

+73822554111

Sponsors and collaborators

Lead sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Other

Registry information

Official study title

New Challenges for the Population on the Path to Achieving Active Longevity: an Online Survey of Respondents Using Telecommunication Technologies

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
Dec 7, 2023
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.